OxSonics was spun out from the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (“BUBBL”) of the Institute of Biomedical Engineering at the University of Oxford in 2014.

The Company is developing ground-breaking ultrasound technology that uses proprietary Sono-Sensitive Particles (SSPs) to increase the tumour penetration of cancer drugs. The SSPs can be delivered in combination with any type of cancer drug without the need for reformulation or derivatisation, increasing the efficacy and/or reducing the toxicity of the therapy through heightened tumour penetration and localised drug concentration. The technology promises to greatly improve the response rate of patients with solid tumours.

Visit website